Immorna Biotherapeutics granted FDA IND clearance for Phase I/II JCXH-211 study
Immorna Biotherapeutics investigational new drug (IND) application for a Phase I/II study of its cancer therapeutic JCXH-211 intravenous (IV) has…
Immorna Biotherapeutics investigational new drug (IND) application for a Phase I/II study of its cancer therapeutic JCXH-211 intravenous (IV) has…
Anti-obesity drugs will be the most impactful trend of 2024, followed by personalised and precision medicine, immuno-oncology (IO) drug development,…
AbbVie has announced positive data for its antibody-drug conjugate (ADC) therapies, Teliso-V, ABBV-400 and ABBV-706, from Phase I and II…
US-based Rakuten Medical has announced positive interim data from the Phase Ib/II trial of its photoimmunotherapy, ASP-1929, in combination with…
Merck & Co (MSD) has announced positive data for its antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from Phase II and…
Last month, the Oncologic Drugs Advisory Committee (ODAC) for the US Food and Drug Administration (FDA) voted in favour of…
Bristol Myers Squibb’s (BMS) blockbuster cancer therapies Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet the primary endpoint as a…
On April 24, the FDA granted Priority Review to the supplemental Biologics License Application (sBLA) for GSK’s Jemperli (dostarlimab) in…
This week on Pipeline Moves, we kick off by looking at the termination of a Phase II investigator-led trial of…
Ultimovacs has implemented cash-saving strategies, including a 40% workforce reduction, to extend its reserves into Q4 2025. The operational adjustments…